From Yahoo Finance: 2025-05-11 17:17:00

President Trump’s executive order aims to revamp laws allowing Medicare to negotiate prescription drug prices. Drug makers seek to delay negotiations for small-molecule drugs by four years. Trump’s order focuses on cutting healthcare costs and may lead to further changes in pricing negotiations. Medicare’s negotiating powers have been a subject of contention, with drug makers expressing concerns about innovation suppression. White House officials suggest changes to the negotiation process could result in greater savings than under the Biden administration. Corcept Therapeutics Incorporated (CORT) is a biopharmaceutical company developing therapies that regulate cortisol levels. A recent analysis by Canaccord Genuity maintains a bullish stance on CORT, citing growth potential in its Korlym product and expansion into oncology with relacorilant in ovarian cancer. While CORT ranks 8th on the list of best healthcare stocks, investors are encouraged to explore AI stocks for potentially higher returns.



Read more at Yahoo Finance: Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now